MCID: ACT119
MIFTS: 64

Acute Promyelocytic Leukemia

Categories: Genetic diseases, Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Acute Promyelocytic Leukemia

MalaCards integrated aliases for Acute Promyelocytic Leukemia:

Name: Acute Promyelocytic Leukemia 53 12 72 49 24 55 28 14 69
Acute Myeloblastic Leukemia Type 3 12 72 49
Leukemia, Acute Promyelocytic 53 24 13
Aml M3 49 24 55
Apl 53 12 24
Acute Myeloid Leukemia with T(15;17)(q22;q12);(pml/raralpha) and Variants 49 55
Aml with T(15;17)(q22;q12);(pml/raralpha) and Variants 49 55
Acute Myeloblastic Leukemia 3 49 55
Apml 49 55
Leukemia, Acute Promyelocytic, Somatic 53
Leukemia, Promyelocytic, Acute 41
Leukemia Promyelocytic Acute 51
Myeloid Leukemia, Acute, M3 24
Acute Myeloid Leukemia M3 12
M3 Anll 24

Characteristics:

Orphanet epidemiological data:

55
acute promyelocytic leukemia
Prevalence: 1-9/1000000 (United States),1-9/1000000 (Europe),1-9/1000000 (France); Age of onset: Adult; Age of death: elderly;

HPO:

31
acute promyelocytic leukemia:
Inheritance somatic mutation


Classifications:



External Ids:

OMIM 53 612376
Disease Ontology 12 DOID:0060318
ICD10 32 C92.4 C92.40
MeSH 41 D015473
NCIt 46 C3182
SNOMED-CT 64 110004001 28950004
Orphanet 55 ORPHA520
MESH via Orphanet 42 D015473
UMLS via Orphanet 70 C0023487
ICD10 via Orphanet 33 C92.4
MedGen 39 C0023487
SNOMED-CT via HPO 65 124975008
UMLS 69 C0023487

Summaries for Acute Promyelocytic Leukemia

NIH Rare Diseases : 49 Acute promyelocytic leukemia (APL) is an aggressive type of acute myeloid leukemia in which there are too many immature blood-forming cells (promyelocytes) in the blood and bone marrow. This build up of promyelocytes leads to a shortage of normal white and red blood cells and platelets in the body. The signs and symptoms of APL include an increased risk to both bleed and form blood clots. Individuals may also experience excessive tiredness, pain in affected areas, loss of appetite, and weight loss. APL usually occurs in middle-aged adults, but can be diagnosed at any age. It is caused by a mutation that is acquired over a person's lifetime, usually involving a translocation between chromosomes 15 and 17. Treatment may include the use of all-trans retinoic acid (ATRA) and arsenic trioxide or anthracycline-based chemotherapy. Last updated: 1/18/2017

MalaCards based summary : Acute Promyelocytic Leukemia, also known as acute myeloblastic leukemia type 3, is related to leukemia and myeloid leukemia, and has symptoms including abnormal granulocytopoietic cell morphology An important gene associated with Acute Promyelocytic Leukemia is NUMA1 (Nuclear Mitotic Apparatus Protein 1), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Trisenox and Arsenic trioxide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 An acute myeloid leukemia characterized by accumulation of promyelocytes in the bone marrow and by a translocation between chromosomes 15 and 17.

Genetics Home Reference : 24 Acute promyelocytic leukemia is a form of acute myeloid leukemia, a cancer of the blood-forming tissue (bone marrow). In normal bone marrow, hematopoietic stem cells produce red blood cells (erythrocytes) that carry oxygen, white blood cells (leukocytes) that protect the body from infection, and platelets (thrombocytes) that are involved in blood clotting. In acute promyelocytic leukemia, immature white blood cells called promyelocytes accumulate in the bone marrow. The overgrowth of promyelocytes leads to a shortage of normal white and red blood cells and platelets in the body, which causes many of the signs and symptoms of the condition.

OMIM : 53 Acute promyelocytic leukemia (APL) is associated with 2 cardinal features: a granulocytic differentiation block and reciprocal and balanced translocations that always involve rearrangement of the RARA gene (180240). The most frequent translocation is t(15,17)(q21;q22), which fuses the RARA gene with the PML gene (102578) and represents more than 98% of APL (Vitoux et al., 2007). (612376)

Wikipedia : 72 Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid... more...

Related Diseases for Acute Promyelocytic Leukemia

Diseases related to Acute Promyelocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 143)
# Related Disease Score Top Affiliating Genes
1 leukemia 32.8 FLT3 NPM1 PML RARA ZBTB16
2 myeloid leukemia 31.6 CD33 FLT3 NPM1 RARA
3 leukemia, acute myeloid 31.1 ANPEP CASP3 CD33 FLT3 NCOR1 NCOR2
4 leukemia, chronic myeloid 30.9 CASP3 CD33 FLT3 STAT5B
5 myelodysplastic syndrome 30.7 ANPEP CD33 FLT3 NPM1
6 myeloid sarcoma 30.6 ANPEP FLT3 NPM1
7 cytogenetically normal acute myeloid leukemia 30.5 FLT3 NPM1
8 aleukemic leukemia cutis 30.5 ANPEP CD33 FLT3 NPM1 RARA
9 acute leukemia 30.2 ANPEP CD33 FLT3
10 antiphospholipid syndrome 11.3
11 atrichia with papular lesions 11.2
12 lipodystrophy, partial, acquired 11.1
13 acute myeloblastic leukemia without maturation 10.7 FLT3 NPM1
14 acute myeloblastic leukemia with maturation 10.7 FLT3 NPM1
15 reticulosarcoma 10.6 ANPEP CASP3 NPM1
16 keratomalacia 10.6 CYP26A1 RARA RARS
17 bone marrow cancer 10.5 ANPEP FLT3 STAT5B
18 precursor t-cell acute lymphoblastic leukemia 10.5 ANPEP CD33 FLT3
19 mediastinal cancer 10.4 ANPEP CD33
20 complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy 10.3
21 intracranial hypertension, idiopathic 10.3
22 thrombosis 10.3
23 disseminated intravascular coagulation 10.2
24 bone marrow necrosis 10.1
25 lymphoma 10.1
26 blood group, i system 10.0
27 multiple sclerosis 10.0
28 polykaryocytosis inducer 10.0
29 hematopoietic stem cell transplantation 10.0
30 hepatitis 10.0
31 hereditary wilms' tumor 10.0
32 endotheliitis 10.0
33 hypercalcemia, infantile, 1 10.0
34 neutrophilia, hereditary 10.0
35 budd-chiari syndrome 10.0
36 pancytopenia 10.0
37 myeloproliferative neoplasm 10.0
38 wilms tumor 1 9.9
39 aging 9.9
40 wilms tumor 5 9.9
41 body mass index quantitative trait locus 1 9.9
42 myocardial infarction 9.9
43 aplastic anemia 9.9
44 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 9.9
45 aspergillosis 9.9
46 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.9
47 wilms tumor 6 9.9
48 hemophagocytic lymphohistiocytosis 9.9
49 sarcoma 9.9
50 leukostasis 9.9

Graphical network of the top 20 diseases related to Acute Promyelocytic Leukemia:



Diseases related to Acute Promyelocytic Leukemia

Symptoms & Phenotypes for Acute Promyelocytic Leukemia

Clinical features from OMIM:

612376

Human phenotypes related to Acute Promyelocytic Leukemia:

31
# Description HPO Frequency HPO Source Accession
1 abnormal granulocytopoietic cell morphology 31 HP:0012135
2 acute promyelocytic leukemia 31 HP:0004836

GenomeRNAi Phenotypes related to Acute Promyelocytic Leukemia according to GeneCards Suite gene sharing:

25 (show all 31)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.87 STAT5B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.87 FLT3
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.87 NCOR1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.87 FLT3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.87 STAT5B FLT3 NCOR1 NUMA1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.87 FLT3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.87 FLT3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.87 STAT5B FLT3
9 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.87 STAT5B
10 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.87 NCOR1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.87 NCOR1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-158 9.87 NUMA1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.87 FLT3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.87 NUMA1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.87 STAT5B
16 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.87 NUMA1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.87 STAT5B
18 Increased shRNA abundance (Z-score > 2) GR00366-A-215 9.87 NUMA1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-24 9.87 NCOR1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.87 FLT3
21 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.87 STAT5B
22 Increased shRNA abundance (Z-score > 2) GR00366-A-4 9.87 NCOR1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.87 NUMA1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.87 STAT5B
25 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.87 NCOR1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.87 NUMA1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.87 STAT5B
28 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.87 FLT3
29 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.87 NUMA1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.87 NCOR1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.87 NUMA1

MGI Mouse Phenotypes related to Acute Promyelocytic Leukemia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.13 CASP3 CYP26A1 FLT3 NCOR1 NCOR2 NPM1
2 hematopoietic system MP:0005397 10 ANPEP CASP3 FLT3 NCOR1 NCOR2 NPM1
3 immune system MP:0005387 9.9 NCOR2 NPM1 PML PRKAR1A RARA STAT5B
4 liver/biliary system MP:0005370 9.5 NCOR1 NCOR2 NPM1 PRKAR1A RARA STAT5B
5 neoplasm MP:0002006 9.1 FLT3 NPM1 PML PRKAR1A RARA ZBTB16

Drugs & Therapeutics for Acute Promyelocytic Leukemia

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Trisenox 17 45 ARSENIC TRIOXIDE Cell Therapeutics September 2000

Drugs for Acute Promyelocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Arsenic trioxide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 1327-53-3 518740
2
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
3
Daunorubicin Approved Phase 4,Phase 3,Phase 2 20830-81-3 30323
4
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 58957-92-9 42890
5
Mitoxantrone Approved, Investigational Phase 4,Phase 3 65271-80-9 4212
6
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
8
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
9 Thiotepa Approved, Investigational Phase 4,Phase 1 52-24-4 5453
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3 50-02-2 5743
11
Tretinoin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 302-79-4 5538
12 Analgesics Phase 4,Phase 3
13 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
15 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
17 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
18 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
21 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
22 6-Mercaptopurine Phase 4,Phase 3,Phase 2
23 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Dermatologic Agents Phase 4,Phase 3,Phase 1,Phase 2
26 Keratolytic Agents Phase 4,Phase 3,Phase 1,Phase 2
27 Antilymphocyte Serum Phase 4,Phase 2
28 Antiemetics Phase 4,Phase 3,Phase 2
29 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
30 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
31 Autonomic Agents Phase 4,Phase 3,Phase 2
32 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
33 glucocorticoids Phase 4,Phase 3,Phase 2
34 Hormone Antagonists Phase 4,Phase 3,Phase 2
35 Hormones Phase 4,Phase 3,Phase 2
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
37 BB 1101 Phase 4,Phase 3
38 Dexamethasone acetate Phase 4,Phase 3 1177-87-3
39
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
40
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
41
Thioguanine Approved Phase 3 154-42-7 2723601
42
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1 320-67-2 9444
43
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
44
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
45
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
46
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
47
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
48
Asparaginase Approved, Investigational Phase 3 9015-68-3
49
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 657311 5754
50
Captopril Approved Phase 3 62571-86-2 44093

Interventional clinical trials:

(show top 50) (show all 157)

# Name Status NCT ID Phase Drugs
1 Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
2 AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia Unknown status NCT00180128 Phase 4 all-trans retinoid acid;idarubicin;mitoxantrone;daunorubicin;cytarabine
3 Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Completed NCT00465933 Phase 4 AIDA
4 Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Completed NCT00408278 Phase 4 ATRA;Idarubicina;Mitoxantrone;ARA-C
5 Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Completed NCT00504764 Phase 4 Arsenic Trioxide;ATRA
6 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
7 Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL Recruiting NCT01987297 Phase 4 ATRA+arsenic;ATRA+chemo
8 A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia Enrolling by invitation NCT02200978 Phase 4 ATO;RIF;ATRA;mitoxantrone;Ara-C;MTX;6MP
9 Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia Unknown status NCT00517712 Phase 2, Phase 3 Single agent arsenic trioxide
10 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia Unknown status NCT00002701 Phase 3 busulfan;cyclophosphamide;cytarabine;etoposide;idarubicin;mercaptopurine;methotrexate;mitoxantrone hydrochloride;thioguanine;tretinoin
11 Acute Promyelocytic Leukemia 2006 (APL) Unknown status NCT00378365 Phase 3
12 Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients Unknown status NCT01633099 Phase 3 Decitabine
13 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
14 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
15 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia Completed NCT00866918 Phase 3 arsenic trioxide;mitoxantrone hydrochloride;idarubicin;tretinoin;cytarabine;mercaptopurine tablet;methotrexate
16 S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia Completed NCT00492856 Phase 3 mercaptopurine;methotrexate;tretinoin
17 Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia Completed NCT00003934 Phase 3 tretinoin;daunorubicin hydrochloride;cytarabine;mercaptopurine;methotrexate;arsenic trioxide
18 Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission Completed NCT00962767 Phase 3 gemtuzumab ozogamicin;ATRA plus 6-MP and MTX
19 A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL) Completed NCT00591526 Phase 3 Arac
20 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia Completed NCT00003436 Phase 3 amsacrine;asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;methotrexate;mitoxantrone hydrochloride;therapeutic hydrocortisone
21 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
22 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
23 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
24 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
25 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
26 Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia Recruiting NCT02688140 Phase 3 Arsenic trioxide;Idarubicin;Cytarabine;Tretinoin;Mitoxantrone;Mercaptopurine;Methotrexate
27 Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF) Recruiting NCT02899169 Phase 3 Realgar-Indigo naturalis formula;all-trans retinoic acid;Arsenic trioxide;Hydroxyurea
28 Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia Recruiting NCT02339740 Phase 3 Arsenic Trioxide;Cytarabine;Dexamethasone;Idarubicin;Mitoxantrone Hydrochloride;Tretinoin
29 Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia Recruiting NCT01226303 Phase 3 ATRA;ATRA + IDA
30 A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old Recruiting NCT03257241 Phase 3 A arm (DA-90);B arm (DAC);A arm (CLAG-M);B arm (FLAG-IDA)
31 An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia Recruiting NCT03151408 Phase 3 Pracinostat;Placebos;Azacitidine
32 Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations Recruiting NCT02272478 Phase 3 Arm A Mylotarg;Arm D Cladribine;AC220;Ganetespib
33 Phase III Trial in Acute Promyelocytic Leukemia Patients Active, not recruiting NCT00482833 Phase 3 arsenic trioxide;idarubicin;mercaptopurine;methotrexate;all-trans retinoic acid;all-trans retinoic acid (ATRA)
34 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
35 Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia Unknown status NCT00675870 Phase 2 NRX 195183 Soft Gelatin Capsule
36 FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML Unknown status NCT00559221 Phase 2 FLAG+IDA
37 Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML Unknown status NCT00529880 Phase 2 Fludarabine , cytarabine
38 Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible Unknown status NCT02261779 Phase 1, Phase 2 Tranylcypromine;Tretinoin
39 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
40 Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia Completed NCT00008697 Phase 1, Phase 2 arsenic trioxide
41 Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission Completed NCT00002609 Phase 2 cytarabine;idarubicin
42 Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia Completed NCT00276601 Phase 2 arsenic trioxide;cytarabine;daunorubicin hydrochloride;mercaptopurine;methotrexate;tretinoin
43 S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia Completed NCT00551460 Phase 2 arsenic trioxide;gemtuzumab ozogamicin;mercaptopurine;methotrexate;tretinoin
44 Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia Completed NCT00016159 Phase 2 arsenic trioxide;idarubicin;tretinoin
45 Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL Completed NCT00520208 Phase 2 Tamibarotene
46 All-trans Retinoic Acid, and Arsenic +/- Gemtuzumab Completed NCT00413166 Phase 2 All-Trans Retinoic Acid (ATRA);Arsenic Trioxide (ATO);Idarubicin
47 Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector Completed NCT01428128 Phase 2 Arsenic Trioxide
48 Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible Completed NCT01361334 Phase 2 Pazopanib
49 Study of Arsenic Trioxide in Small Cell Lung Cancer Completed NCT01470248 Phase 2 Arsenic Trioxide
50 Selinexor (KPT-330) in Older Patients With Relapsed AML Completed NCT02088541 Phase 2 Selinexor;Hydroxyurea;Ara-C;azacitidine;Decitabine

Search NIH Clinical Center for Acute Promyelocytic Leukemia

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: leukemia, promyelocytic, acute

Genetic Tests for Acute Promyelocytic Leukemia

Genetic tests related to Acute Promyelocytic Leukemia:

# Genetic test Affiliating Genes
1 Acute Promyelocytic Leukemia 28 NUMA1 RARA

Anatomical Context for Acute Promyelocytic Leukemia

MalaCards organs/tissues related to Acute Promyelocytic Leukemia:

38
Myeloid, Bone, Bone Marrow, Brain, Skin, Lung, Testes

Publications for Acute Promyelocytic Leukemia

Articles related to Acute Promyelocytic Leukemia:

(show top 50) (show all 1121)
# Title Authors Year
1
The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia. ( 29232592 )
2018
2
Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia: a case report and literature review. ( 29404721 )
2018
3
Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA. ( 29407588 )
2018
4
Chloroquine exerts antitumor effects on NB4 acute promyelocytic leukemia cells and functions synergistically with arsenic trioxide. ( 29434902 )
2018
5
Vernodalol mediates antitumor effects in acute promyelocytic leukemia cells. ( 29434929 )
2018
6
Inducing Apoptosis and Decreasing Cell Proliferation in Human Acute Promyelocytic Leukemia Through Regulation Expression of<i>CASP3</i>by Let-7a-5p Blockage. ( 29398802 )
2018
7
Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy. ( 29362482 )
2018
8
Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemia. ( 29289982 )
2018
9
Relapse of acute promyelocytic leukemia in the external auditory canal confirmed by PML/RARA dual-fusion and RARA break-apart fluorescence in situ hybridization. ( 29387977 )
2018
10
Molecular Heterogeneity in Acute Promyelocytic Leukemia - a Single Center Experience from India. ( 29326799 )
2018
11
miR-218 inhibits acute promyelocytic leukemia cell growth by targeting BMI-1. ( 29344251 )
2017
12
Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic Leukemia. ( 28340577 )
2017
13
Microgranular acute promyelocytic leukemia presenting with leukopenia and an unusual immunophenotype. ( 26806461 )
2017
14
Analysis of early death in newly diagnosed acute promyelocytic leukemia patients. ( 29390508 )
2017
15
The clinical significance of FLT3 ITD mutation on the prognosis of adult acute promyelocytic leukemia. ( 29251252 )
2017
16
Influence of body mass index on incidence and prognosis of acute myeloid leukemia and acute promyelocytic leukemia: A meta-analysis. ( 29269861 )
2017
17
Rapamycin induces human acute promyelocytic leukemia cell HL-60 autophagic apoptosis. ( 29243797 )
2017
18
Regulatory mechanism and functional analysis of S100A9 in acute promyelocytic leukemia cells. ( 28063140 )
2017
19
Clinical impact of<i>BAALC</i>expression in high-risk acute promyelocytic leukemia. ( 29296827 )
2017
20
Expression of the promyelocytic leukemia protein without the nuclear localization signal as a novel diagnostic marker for acute promyelocytic leukemia. ( 28075463 )
2017
21
Pancreatitis in Acute Promyelocytic Leukemia: Drug-induced or Differentiation Syndrome? ( 29200694 )
2017
22
Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens. ( 28238096 )
2017
23
Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1I^. ( 28343272 )
2017
24
Identification of novel recurrent<i>STAT3-RARA</i>fusions in acute promyelocytic leukemia lacking t(15;17)(q22;q12)/<i>PML-RARA</i>. ( 29237593 )
2017
25
Progress and criticalities in the management of acute promyelocytic leukemia. ( 29245895 )
2017
26
Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia. ( 29266395 )
2017
27
Ring Chromosome 10 in a Case of Acute Promyelocytic Leukemia. ( 27981936 )
2016
28
Management of differentiation syndrome in an elderly patient with acute promyelocytic leukemia who subsequently developed refractory anemia with ring sideroblasts. ( 27073113 )
2016
29
A network including PU.1, Vav1 and miR-142-3p sustains ATRA-induced differentiation of acute promyelocytic leukemia cells - a short report. ( 27480083 )
2016
30
Pseudotumor Cerebri in Acute Promyelocytic Leukemia Patients on Intergroup Protocol 0129: Clinical Description and Recommendations forA New Diagnostic Criteria. ( 26724834 )
2016
31
Brain infarction and blasts with bilobed nuclei in a patient with monocytic acute myeloid leukemia mimicking acute promyelocytic leukemia. ( 26802620 )
2016
32
An Unusual Case of Acute Promyelocytic Leukemia Presenting With Hypoplastic Bone Marrow and Pancytopenia. ( 26992265 )
2016
33
Nrf2 activation ameliorates cytotoxic effects of arsenic trioxide in acute promyelocytic leukemia cells through increased glutathione levels and arsenic efflux from cells. ( 27317373 )
2016
34
NPM and BRG1 Mediate Transcriptional Resistance to Retinoic Acid in Acute Promyelocytic Leukemia. ( 26997274 )
2016
35
Repression of CDKN2C caused by PML/RARI+ binding promotes the proliferation and differentiation block in acute promyelocytic leukemia. ( 27888400 )
2016
36
Severe stomatitis and ileocecal perforation developed after all-trans retinoic acid monotherapy in an HLA-B51-positive patient with acute promyelocytic leukemia. ( 27384858 )
2016
37
Erythema multiforme due to arsenic trioxide in a case of acute promyelocytic leukemia: A diagnostic challenge. ( 27114640 )
2016
38
NLSa89RARI+ modulates acute promyelocytic leukemia NB4 cell proliferation and differentiation via the PI3K/AKT pathway. ( 27840989 )
2016
39
A novel PAD4/SOX4/PU.1 signaling pathway is involved in the committed differentiation of acute promyelocytic leukemia cells into granulocytic cells. ( 26673819 )
2016
40
Identification of miR-125b targets involved in acute promyelocytic leukemia cell proliferation. ( 27613090 )
2016
41
Severe Acute Axonal Neuropathy following Treatment with Arsenic Trioxide for Acute Promyelocytic Leukemia: a Case Report. ( 27158436 )
2016
42
Co-operative leukemogenesis in acute myeloid leukemia and acute promyelocytic leukemia reveals C/EBPI+ as a common target of TRIB1 and PML/RARA. ( 27390356 )
2016
43
A Complicated Case of Acute Promyelocytic Leukemia in the Second Trimester of Pregnancy Successfully Treated with All-trans-Retinoic Acid. ( 25821608 )
2015
44
Absolute quantification of the pretreatment PML-RARA transcript defines the relapse risk in acute promyelocytic leukemia. ( 25944686 )
2015
45
Late Onset Post-Transfusion Hepatitis E Developing during Chemotherapy for Acute Promyelocytic Leukemia. ( 25786459 )
2015
46
Successful treatment of acute promyelocytic leukemia with a t(X;17)(p11.4;q21) and BCOR-RARA fusion gene. ( 25790901 )
2015
47
Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance. ( 25822503 )
2015
48
Restoration of CCAAT enhancer binding protein I+ P42 induces myeloid differentiation and overcomes all-trans retinoic acid resistance in human acute promyelocytic leukemia NB4-R1 cells. ( 26397153 )
2015
49
Rhinocerebral Mucormycosis in a Patient with Acute Promyelocytic Leukemia. ( 25805690 )
2015
50
Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients. ( 26294332 )
2015

Variations for Acute Promyelocytic Leukemia

Copy number variations for Acute Promyelocytic Leukemia from CNVD:

7 (show all 28)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 17351 1 142487224 245120412 Gain Acute promyelocytic leukemia
2 29128 1 227843862 227867765 Deletion EGLN1 Acute promyelocytic leukemia
3 44777 10 62496958 68046104 Deletion Acute promyelocytic leukemia
4 71119 12 6755671 29248257 Deletion Acute promyelocytic leukemia
5 78273 13 49630676 50510777 Deletion DLEU7 Acute promyelocytic leukemia
6 78274 13 49630676 50510777 Deletion FAM10A4 Acute promyelocytic leukemia
7 78275 13 49630676 50510777 Deletion GUCY1B2 Acute promyelocytic leukemia
8 78767 13 56784440 114051465 Duplication Acute promyelocytic leukemia
9 93669 15 57244668 100182183 Duplication Acute promyelocytic leukemia
10 94970 15 72224840 100192115 Duplication Acute promyelocytic leukemia
11 108134 17 18901 21459693 Deletion Acute promyelocytic leukemia
12 108602 17 21491135 35542587 Duplication Acute promyelocytic leukemia
13 123386 18 7192739 7657575 Duplication PTPRM Acute promyelocytic leukemia
14 157044 21 1 48129895 Tri Acute promyelocytic leukemia
15 158722 21 36234195 46924583 Duplication Acute promyelocytic leukemia
16 181722 4 125190507 126521903 Deletion Acute promyelocytic leukemia
17 214094 6 5545437 8054930 Deletion Acute promyelocytic leukemia
18 220370 7 137795618 137920872 Translate TIF1 Acute promyelocytic leukemia
19 226739 7 61522282 158554645 Deletion Acute promyelocytic leukemia
20 228938 7 85414972 86445002 Deletion DMTF1 Acute promyelocytic leukemia
21 228939 7 85414972 86445002 Deletion GRM3 Acute promyelocytic leukemia
22 228940 7 85414972 86445002 Deletion KIAA1324L Acute promyelocytic leukemia
23 230737 8 1 146364022 Tri Acute promyelocytic leukemia
24 233093 8 122607785 132092760 Duplication Acute promyelocytic leukemia
25 254363 9 64207745 111479523 Deletion Acute promyelocytic leukemia
26 256567 9 94435025 94710006 Duplication C9orf3 Acute promyelocytic leukemia
27 256568 9 94435025 94710006 Duplication FBP1 Acute promyelocytic leukemia
28 256569 9 94435025 94710006 Duplication FBP2 Acute promyelocytic leukemia

Expression for Acute Promyelocytic Leukemia

Search GEO for disease gene expression data for Acute Promyelocytic Leukemia.

Pathways for Acute Promyelocytic Leukemia

GO Terms for Acute Promyelocytic Leukemia

Cellular components related to Acute Promyelocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein complex GO:0043234 9.85 FLT3 NPM1 NUMA1 PRKAR1A ZBTB16
2 nuclear matrix GO:0016363 9.61 NCOR2 NUMA1 PML
3 spindle microtubule GO:0005876 9.5 NCOR1 NUMA1 TBL1XR1
4 nucleoplasm GO:0005654 9.44 CASP3 FIP1L1 NABP1 NCOR1 NCOR2 NPM1
5 histone deacetylase complex GO:0000118 9.43 NCOR1 NCOR2 TBL1XR1
6 spindle pole centrosome GO:0031616 9.4 NPM1 NUMA1
7 transcriptional repressor complex GO:0017053 9.26 NCOR1 NCOR2 TBL1XR1 ZBTB16
8 cytosol GO:0005829 10.18 CASP3 FLT3 NABP1 NCOR1 NPM1 NUMA1
9 nucleus GO:0005634 10.06 ANPEP CASP3 CD33 FIP1L1 FLT3 NABP1

Biological processes related to Acute Promyelocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.55 CD33 NPM1 PML RARA ZBTB16
2 regulation of lipid metabolic process GO:0019216 9.5 NCOR1 NCOR2 TBL1XR1
3 retinoic acid receptor signaling pathway GO:0048384 9.37 PML RARA
4 negative regulation of activated T cell proliferation GO:0046007 9.26 CASP3 PRKAR1A
5 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 8.96 NCOR1 NCOR2
6 response to estradiol GO:0032355 8.92 CASP3 NCOR2 RARA STAT5B

Molecular functions related to Acute Promyelocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein domain specific binding GO:0019904 9.67 NUMA1 PRKAR1A RARA ZBTB16
2 protein complex binding GO:0032403 9.62 CASP3 FLT3 NCOR2 NUMA1
3 histone deacetylase binding GO:0042826 9.58 NCOR1 NCOR2 RARA
4 transcription corepressor activity GO:0003714 9.46 NCOR1 NCOR2 RARA TBL1XR1
5 ligand-dependent nuclear receptor binding GO:0016922 9.43 NCOR1 NCOR2
6 RNA polymerase II regulatory region DNA binding GO:0001012 8.96 NCOR2 RARA
7 glucocorticoid receptor binding GO:0035259 8.8 FLT3 NCOR2 STAT5B
8 protein binding GO:0005515 10.19 CASP3 CD33 FIP1L1 FLT3 NABP1 NCOR1

Sources for Acute Promyelocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....